<DOC>
	<DOCNO>NCT02150720</DOCNO>
	<brief_summary>The main hypothesis clinical trial use intra-articular tranexamic acid fibrin glue plus usual hemostasis reduce least 25 % postoperative blood loss respect usual hemostasis patient undergoing subcapital femoral fracture .</brief_summary>
	<brief_title>Prevention Postoperative Bleeding Subcapital Femoral Fractures</brief_title>
	<detailed_description />
	<mesh_term>Fractures , Bone</mesh_term>
	<mesh_term>Hip Fractures</mesh_term>
	<mesh_term>Hemorrhage</mesh_term>
	<mesh_term>Femoral Fractures</mesh_term>
	<mesh_term>Postoperative Hemorrhage</mesh_term>
	<mesh_term>Fibrin Tissue Adhesive</mesh_term>
	<mesh_term>Tranexamic Acid</mesh_term>
	<criteria>Patients 18 year Patients unilateral subcapital femoral fracture Patients require hip replacement ( total partial ) Signed informed consent patient legal representative Known allergy fibrin glue tranexamic acid Multiple fracture Pathological fracture Contraceptives estrogen therapy Use blood salvage surgery History compatible thromboembolic disease : Cerebral vascular accident Ischemic heart disease ( myocardial infarction , angina ) Deep vein thrombosis Pulmonary Embolism Peripheral arterial vasculopathy Patients thrombogenic arrhythmia Patients cardiovascular stent Prothrombotic alteration coagulation</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>Hip fracture</keyword>
	<keyword>Clinical Trial</keyword>
	<keyword>Randomized</keyword>
	<keyword>Fibrin glue</keyword>
	<keyword>Tranexamic acid</keyword>
	<keyword>Blood loss</keyword>
</DOC>